大腸の忠節性の喪失は,多線形の可塑性と転移を可能にします

Patrizia Cammareri^1,2, Michela Raponi^1,2,3, Yourae Hong⁴

¹Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, UK.

Nature

|June 4, 2025

まとめ

大腸がん細胞におけるATRXの喪失は,細胞の可塑性と大腸のアイデンティティの喪失を促すことで転移を引き起こす. ATRXとHNF4Aは系統の可塑性を抑制し腫瘍の広がりを抑制する.

科学分野:

腫瘍学
エピジェネティクス
分子生物学

背景:

癌細胞の可塑性は転移の重要な要因であり,しばしば遺伝的変化なしに発生し,表遺伝的調節が示唆される.
結腸直腸がんの転移を制御するエピジェネティックメカニズムはまだ十分に理解されていません.

研究の目的:

結腸癌における結腸系統の忠誠性と転移の重要な調節因子を特定する.
癌細胞の可塑性と転移の背後にある表遺伝的メカニズムを解明する.

主な方法:

染色体改造酵素ATRXは,大腸がんの調節剤として研究されました.
クロマチンのアクセシビリティとエンハンサーマッピングは,遺伝子調節を分析するために使用された.
特定の細胞状態と発現シグネチャーのためのヒト患者サンプル分析

主要な成果:

ATRXの喪失は腫瘍の侵入と転移を促進し,大腸の表皮のアイデンティティの喪失につながります.
ATRXの喪失で高度なプラスティック性および状細胞状態の出現が観察されました.
転写因子HNF4Aの活性低下は,これらの表型の媒介体として特定されました.
状細胞と関連する発現シグネチャーは,攻撃的な疾患と悪い予後と相関しています.

結論:

ATRXは結腸系統の忠節性の重要な調節体であり,大腸がんの転移を抑制する.
ATRXとHNF4Aは結腸上皮の同一性を表遺伝的に維持し,系統の可塑性と転移の抑制剤として作用する.
状細胞の特定と予後的意義は,大腸がんの進行に関する新しい洞察を提供します.

さらに関連する動画

11:43

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones

Published on: November 30, 2016

12.9K

28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.5K

関連する概念動画

02:30

Metastasis

5.7K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

5.7K

01:23

Renewal of Intestinal Stem Cells

2.7K

The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...

2.7K

02:53

Adaptive Mechanisms in Cancer Cells

6.0K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

6.0K

02:40

Cancer Stem Cells and Tumor Maintenance

5.1K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

5.1K

01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

2.2K

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

2.2K

02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.1K

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...